The world now has an Ebola vaccine, in historic EU approval

The vaccine is 97.5% effective in protecting against the Zaire species of Ebola, according to the World Health Organization.

The world now has an Ebola vaccine, in historic EU approval

Ebola virus

Centers for Disease Control and Prevention
  • The European Medicines Agency granted special approval for an Ebola vaccine called Ervebo.
  • Ervebo has proven remarkably effective in clinical trials conducted in Africa.
  • An Ebola outbreak has killed more than 2,000 people in the Democratic Republic of Congo since August 2018.


Health regulators in Europe have issued the world's first approval for a vaccine against Ebola, and it's estimated to become widely available in 2020.

The European Medicines Agency granted a conditional marketing authorization this week that allows the U.S. pharmaceutical company Merck to market the vaccine, called Ervebo. Conditional marketing authorizations help to fast-track the approval process for drugs and therapies that treat "unmet medical needs." That's important when fighting often-deadly viral diseases like Ebola.

Since August 2018, Ebola has killed more than 2,000 people in the Democratic Republic of Congo (DRC). Besides the 2014 West African outbreak that killed more than 11,000 people, the 2018 DRC outbreak is so far the deadliest on record. And the number of cases continues to rise. But experimental vaccination programs have helped curb infection rates. In these programs, Ervebo was strikingly effective, showing an estimated protective efficacy of 97.5 percent, as the World Health Organization reported in April.

Centers for Disease Control and Prevention

"Finding a vaccine as soon as possible against this terrible virus has been a priority for the international community ever since Ebola hit West Africa five years ago," Vytenis Andriukaitis, commissioner in charge of Health and Food Safety at the EU's European Commission, said in a statement. "Today's decision is therefore a major step forward in saving lives in Africa and beyond."

Ervebo protects against a particularly infectious ebolavirus species called Zaire, one of four species known to infect humans. Zaire can also infect animals, like macaques. In 2005, researchers at the Public Health Agency of Canada's National Microbiology Laboratory developed an Ebola vaccine that protected macaques 100 percent of the time. But lack of funding and regulatory hurdles meant it'd take years, maybe decades, to prove the vaccine was safe and effective in humans.

Then the 2014 West African outbreak struck. With the need for an effective vaccine made clear, Merck obtained the license to Ervebo, known as rVSV-ZEBOV-GP, and soon the vaccine was being administered to people in Guinea as part of a clinical trial. The vaccination strategy there was to inoculate people who'd been in contact with others who'd been infected with Ebola. This is called ring vaccination.

But while ring vaccination was effective in preventing the spread of Zaire, it remains unclear just how long the protective effects last. That's a critical question for, say, health workers who get vaccinated to protect themselves against infection that might occur months later. There are also other ebolavirus species that other vaccines would need to address, such as the deadly Sudan species.

In addition to the conditional marketing authorization issued by the European Medicines Agency, the World Health Organization has "prequalified" the Ervebo, meaning it meets standards for safety and efficacy.

"[Prequalification] is a historic step towards ensuring the people who most need it are able to access this life-saving vaccine," WHO Director-General Dr. Tedros Adhanom Ghebreyesus said in the announcement. "Five years ago, we had no vaccine and no therapeutics for Ebola. With a prequalified vaccine and experimental therapeutics, Ebola is now preventable and treatable."

In the U.S., the Food and Drug Administration is expected to decide on approval in March 2020.

‘Designer baby’ book trilogy explores the moral dilemmas humans may soon create

How would the ability to genetically customize children change society? Sci-fi author Eugene Clark explores the future on our horizon in Volume I of the "Genetic Pressure" series.

Surprising Science
  • A new sci-fi book series called "Genetic Pressure" explores the scientific and moral implications of a world with a burgeoning designer baby industry.
  • It's currently illegal to implant genetically edited human embryos in most nations, but designer babies may someday become widespread.
  • While gene-editing technology could help humans eliminate genetic diseases, some in the scientific community fear it may also usher in a new era of eugenics.
Keep reading Show less

Massive 'Darth Vader' isopod found lurking in the Indian Ocean

The father of all giant sea bugs was recently discovered off the coast of Java.

A close up of Bathynomus raksasa

SJADE 2018
Surprising Science
  • A new species of isopod with a resemblance to a certain Sith lord was just discovered.
  • It is the first known giant isopod from the Indian Ocean.
  • The finding extends the list of giant isopods even further.
Keep reading Show less

Discovery of two giant radio galaxies hints at more to come

The newly discovered galaxies are 62x bigger than the Milky Way.

This image shows most of the giant radio galaxy MGTC J095959.63+024608.6; in red is the radio light from the giant radio galaxy, as seen by MeerKAT. It is placed ontop of a typical image of the night sky.

I. Heywood, University of Oxford / Rhodes University / South African Radio Astronomy Observatory / CC BY 4.0.
Surprising Science
  • Two recently discovered radio galaxies are among the largest objects in the cosmos.
  • The discovery implies that radio galaxies are more common than previously thought.
  • The discovery was made while creating a radio map of the sky with a small part of a new radio array.
Keep reading Show less

The secret life of maladaptive daydreaming

Daydreaming can be a pleasant pastime, but people who suffer from maladaptive daydreamers are trapped by their fantasies.

(Photo: Wikimedia Commons)
Mind & Brain
  • Maladaptive daydreamers can experience intricate, vivid daydreams for hours a day.
  • This addiction can result in disassociation from vital life tasks and relationships.
  • Psychologists, online communities, and social pipelines are spreading awareness and hope for many.
  • Keep reading Show less
    Mind & Brain

    Why it's important to admit when you're wrong

    Psychologists point to specific reasons that make it hard for us to admit our wrongdoing.

    Scroll down to load more…
    Quantcast